Germany's 2024 CVOT Summit: Big Wins for Diabetes Heart & Kidney Care

What Is the CVOT Summit — and Why Should US Patients Care?

A study from Germany, published in Cardiovascular Diabetology (2025), summarizes the findings from the 10th annual Cardiovascular Outcome Trial (CVOT) Summit, held virtually in December 2024. Organized by Forschergruppe Diabetes e.V. at the Helmholtz Center Munich, this international congress brings together leading cardiologists, kidney specialists, and diabetes experts from around the world to review the most important new clinical trial data — making it one of the most globally comprehensive diabetes research events of the year.

What makes this international perspective especially valuable for US patients is that the summit synthesizes trial results from multiple countries and health systems, offering a broader evidence base than any single US study could provide. It also draws experts who influence guidelines in Europe and beyond, sometimes identifying treatment insights before they're fully reflected in US clinical practice.

Six Major Drug Trials — Here's What They Found

The 2024 summit focused heavily on six landmark studies involving medications many American patients with diabetes may already be taking or discussing with their doctors:

• Empagliflozin (Jardiance) — EMPACT-MI trial: Examined heart protection after a heart attack in people with diabetes.
• Semaglutide (Ozempic/Wegovy) — STEP-HFpEF-DM and FLOW trials: Showed meaningful improvements in heart failure with preserved pumping function (HFpEF) and significant slowing of chronic kidney disease (CKD) progression.
• Tirzepatide (Mounjaro/Zepbound) — SURMOUNT-OSA and SUMMIT trials: Demonstrated benefits for obstructive sleep apnea (OSA) — a condition extremely common in people with type 2 diabetes — and for a specific type of heart failure.
• Finerenone (Kerendia) — FINEARTS-HF trial: Showed heart failure benefits in patients with preserved ejection fraction.

Beyond the Drugs: Other Key Topics

The summit also addressed several issues directly relevant to everyday diabetes management in the US:

• Continuous Glucose Monitoring (CGM) and Automated Insulin Delivery (AID): Updates reinforced that CGM technology improves outcomes — aligning with current American Diabetes Association (ADA) guidelines encouraging CGM use for most insulin-using patients.
• Early detection of Type 1 diabetes (T1D): Strategies to identify T1D earlier and potentially delay its onset were discussed — an area of growing focus in the US as well.
• Cardio-Kidney-Metabolic (CKM) syndrome: This emerging framework — also now recognized by the American Heart Association — emphasizes that heart disease, kidney disease, obesity, and diabetes must be managed together, not in isolation.
• Plastic pollution and cardiovascular risk: Emerging data on environmental plastic exposure as a CVD risk factor — a topic not yet widely discussed in US patient guidelines but worth watching.
• Nutrition under incretin-based therapy: As more patients use GLP-1 medications, dietary strategies are being updated to account for reduced appetite and muscle mass concerns.

Does This Align With US Guidelines?

Largely, yes. The ADA's 2024 Standards of Care already recommend SGLT2 inhibitors (like empagliflozin) and GLP-1 receptor agonists (like semaglutide) for patients with type 2 diabetes who have established heart or kidney disease. This international summit reinforces and expands that evidence base, particularly for heart failure subtypes and sleep apnea — areas where US guidelines are still evolving.

Why This Matters for US Patients

If you have type 2 diabetes combined with heart disease, kidney disease, obesity, or sleep apnea, the evidence from 2024 strongly suggests that your medication choices can do more than just lower blood sugar — they can protect your organs and potentially extend your life. Talk to your doctor about whether empagliflozin, semaglutide, or tirzepatide may be appropriate for your full health picture, not just your A1C.

Staying informed about your glucose trends is a critical first step. At mdsdiabetes.com, MDS Diabetes offers CGM supplies and diabetes management resources to help you and your care team stay on top of the data that drives these life-changing treatment decisions.

Full Citation

Schnell, Almandoz, Anderson (2025). CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes. Cardiovascular Diabetology. PMID: 40316962. DOI: 10.1186/s12933-025-02700-0. Country of origin: Germany — Forschergruppe Diabetes e.V., Helmholtz Center Munich, Neuherberg (Munich), Germany.